PSMA ADC new drug in Phase II

www.sciencedaily.com/releases/2012/11/121107195922.htm
Phase I results and article.

www.progenics.com/product-pipeline/psma-adc-therapeutic-technology/


PSMA ADC antibody drug conjugate is in a Phase II trial.
clinicaltrials.gov/ct2/results?term=psma+adc&Search=Search

Post Edited (robertC) : 10/14/2013 7:17:11 AM (GMT-6)

Very interesting, novel approach, which could be applied more broadly.

"The drug is made up of a monoclonal antibody, which targets a protein called prostate specific membrane antigen (PSMA), linked to a cancer cell-killing drug called monomethyl auristatin E (MMAE), which disrupts tubulins -- the tiny molecules inside a cell that are essential for cell division. The PSMA antibody drug conjugate (PSMA ADC) binds to the PSMA on the surface of the prostate cancer cell and is absorbed into the cell where the MMAE is released, causing cell cycle arrest and cell death. ... about half of the patients who received doses of 1.8 mg/kg or more showed either a 50% or more reduction in PSA levels, or a fall in CTC in the blood to less than five cells per 7.5 ml of blood, or both"

Phase II trial is now in the recruiting stage, seeking up to 75 patients with hormone-independent, metastatic PC, and are post-chemo.

Post Edited (proscapt) : 11/8/2012 6:48:32 PM (GMT-7)

Hello all! My husband was offered to partake in this trial, just trying to get as much info as we can about the new drug. Does anyone know any good web sites where they talk more about the results? Thank you!

The Phase I trial only measured a couple of markers i.e. PSA and circulating tumor cells. Don't think there is much data yet. Good luck.

www.youtube.com/watch?v=8g-kKnvZwb0

Post Edited (robertC) : 10/14/2013 7:29:35 AM (GMT-6)

Here's an update on the trial. Targeted Agent Demonstrates Activity In Certain Patients With Very Advanced Prostate Cancer. Medscape (2/1, Nelson) reports that “a first-in-class targeted agent has demonstrated activity in patients with very advanced prostate cancer who were refractory to taxane and had progressed on abiraterone (Zytiga) and/or enzalutamide (Xtandi),” according to research presented at the Genitourinary Cancers Symposium, sponsored by ASCO, among others. During “the phase 2 trial of the prostate-specific membrane antigen (PSMA) antibody drug conjugate (ADC), which is under development by Progenics, there was a reduction in several biomarkers.” Approximately “45% of patients experienced a reduction in prostate-specific antigen (PSA) levels of at least 30% and a conversion from unfavorable to favorable circulating tumor cells (CTCs).”